

HIV pre-exposure prophylaxis was associated with no impact on sexually transmitted infection prevalence in a high-prevalence population of predominantly men who have sex with men, Germany, 2018 to 2019

Hendrik Streeck^{1,2}, Klaus Jansen³, Trevor A Crowell^{4,5}, Allahna Esber^{4,5}, Heiko K Jessen⁶, Christiane Cordes⁷, Stefan Scholten⁸, Stephan Schneeweiss⁸, Norbert Brockmeyer^{9,10}, Christoph D Spinner¹¹, Markus Bickel¹², Stefan Esser^{2,13}, Jukka Hartikainen¹⁴, Albrecht Stoehr¹⁵, Clara Lehmann¹⁶, Ulrich Marcus³, Jörg Janne Vehreschild¹⁷, Alexandra Knorr², Anna-Lena Brillen², Carsten Tiemann¹⁷, Merlin L Robb^{4,5}, Nelson L Michael^{4,18}

1. Institute of Virology, University Hospital, University of Bonn, Bonn, Germany
2. Institute of HIV Research, University Duisburg-Essen, Essen, Germany
3. Robert Koch Institute, Berlin, Germany
4. U.S. Military HIV Research Program, Silver Spring, United States
5. Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, United States
6. Private Practice Jessen+Jessen, Berlin, Germany
7. Private Practice Cordes, Berlin, Germany
8. Private Practice Hohenstaufenring, Cologne, Germany
9. WIR-Walk In Ruhr, Center for Sexual Health and Medicine, Bochum, Germany
10. Interdisciplinary Immunological Outpatient Clinic, Center for Sexual Health and Medicine, Department of Dermatology, Venereology and Allergology, Ruhr University Bochum, Bochum, Germany
11. Technical University of Munich, School of Medicine, University Hospital Rechts der Isar, Department of Internal Medicine II, Munich, Germany
12. Infektiologikum Frankfurt, Frankfurt, Germany
13. HPSTD clinic, University Hospital Essen, University Duisburg-Essen, Essen, Germany
14. Private Practice ZIBP, Berlin, Germany
15. Institute for interdisciplinary medicine, Hamburg, Germany
16. University of Cologne, Cologne, Germany
17. Laboratory Krone, Bad Salzuflen, Germany
18. Walter Reed Army Institute of Research, Silver Spring, United States

Correspondence: Hendrik Streeck (hstreeck@uni-bonn.de)

Citation style for this article:

Streeck Hendrik, Jansen Klaus, Crowell Trevor A, Esber Allahna, Jessen Heiko K, Cordes Christiane, Scholten Stefan, Schneeweiss Stephan, Brockmeyer Norbert, Spinner Christoph D, Bickel Markus, Esser Stefan, Hartikainen Jukka, Stoehr Albrecht, Lehmann Clara, Marcus Ulrich, Vehreschild Jörg Janne, Knorr Alexandra, Brillen Anna-Lena, Tiemann Carsten, Robb Merlin L, Michael Nelson L. HIV pre-exposure prophylaxis was associated with no impact on sexually transmitted infection prevalence in a high-prevalence population of predominantly men who have sex with men, Germany, 2018 to 2019. *Euro Surveill*. 2022;27(14):pii=2100591. <https://doi.org/10.2807/1560-7917.ES.2022.27.14.2100591>

Article submitted on 15 Jun 2021 / accepted on 05 Nov 2021 / published on 07 Apr 2022

Introduction: Despite increased use of pre-exposure prophylaxis (PrEP) in Germany, HIV infection rates are not declining and little is known about how this prevention method affects the prevalence of sexually transmitted infections (STI) among men who have sex with men (MSM). **Aim:** We studied, in a large multicentre cohort, STI point prevalence, co-infection rates, anatomical location and influence of PrEP. **Methods:** The BRAHMS study was a prospective cohort study conducted at 10 sites in seven major German cities that enrolled MSM reporting increased sexual risk behaviour. At screening visits, MSM were tested for *Mycoplasma genitalium* (MG), *Neisseria gonorrhoeae* (NG), *Chlamydia trachomatis* (CT) and *Treponema pallidum* (TP), and given a behavioural questionnaire. With binomial regression, we estimated prevalence ratios (PR) and 95% confidence intervals (CI) for the association of PrEP and STI. **Results:** We screened 1,043 MSM in 2018 and 2019, with 53.0% currently using PrEP. At screening, 370 participants (35.5%) had an STI. The most common pathogen was MG in 198 (19.0%) participants,

followed by CT (n=133; 12.8%), NG (n=105; 10.1%) and TP (n=37; 3.5%). Among the 370 participants with at least one STI, 14.6% (n=54) reported STI-related symptoms. Infection prevalence was highest at anorectal site (13.4% MG, 6.5% NG, 10.2% CT). PrEP use was not statistically significant in adjusted models for STI (PR: 1.10; 95% CI: 0.91–1.32), NG/CT, only NG or only CT. **Conclusions:** Prevalence of asymptomatic STI was high, and PrEP use did not influence STI prevalence in MSM eligible for PrEP according to national guidelines.

Introduction

Globally, the number of diagnoses of sexually transmitted infections (STI) has steadily increased in recent years [1]. The World Health Organization (WHO) estimated that in 2016, there were 376 million new infections with *Neisseria gonorrhoeae* (NG), *Chlamydia trachomatis* (CT), *Treponema pallidum* (TP) or *Trichomonas vaginalis* (TV) [1]. While STI diagnoses have increased across the general population, men who have sex

TABLE 1

Select participant characteristics, by HIV pre-exposure prophylaxis usage, upon screening for entry into the BRAHMS cohort, Germany, June 2018 to July 2019 (n = 1,043)

	All participants		Not using PrEP		Using PrEP		p value
	n = 1,043		n = 490		n = 553		
	n	%	n	%	n	%	
Age (years)							
18–29	335	32.1	202	41.2	133	24.1	< 0.001
30–39	482	46.2	210	42.9	272	49.2	
40–49	191	18.3	64	13.1	127	23.0	
50–55	35	3.4	14	2.9	21	3.8	
Sex at birth							
Male	1,042	99.9	489	99.8	553	100.0	0.29
Female	1	0.1	1	0.2	0	0.0	
Gender identity							
Man	1,027	98.5	482	98.4	545	98.6	0.49
Transman	1	0.1	1	0.2	0	0.0	
Other	8	0.8	3	0.6	5	0.9	
Missing	7	0.7	4	0.8	3	0.5	
Sexual orientation							
Gay or homosexual	959	91.9	446	91.0	513	92.8	0.21
Other ^a	74	7.1	40	8.2	34	6.1	
Missing	10	1.0	4	0.8	6	1.1	
Place of birth							
Other country	327	31.4	145	29.6	182	32.9	0.25
Germany	716	68.6	345	70.4	371	67.1	
City							
Berlin	396	38.0	186	38.0	210	38.0	0.049
Bochum	147	14.1	65	13.3	82	14.8	
Cologne	165	15.8	74	15.1	91	16.5	
Essen	77	7.4	46	9.4	31	5.6	
Frankfurt	102	9.8	40	8.2	62	11.2	
Hamburg	31	3.0	11	2.2	20	3.6	
Munich	125	12.0	68	13.9	57	10.3	
Education							
Less than secondary school	31	3.0	14	2.9	17	3.1	0.003
Secondary school	465	44.6	245	50.0	220	39.8	
Undergraduate degree	176	16.9	84	17.1	92	16.6	
Master's or doctorate degree	371	35.6	147	30.0	224	40.5	
Sexual positioning							
Not applicable or missing	189	18.1	84	17.1	105	19.0	0.85
Exclusively receptive	36	3.5	17	3.5	19	3.4	
Exclusively insertive	33	3.2	17	3.5	16	2.9	
Both insertive and receptive	785	75.3	372	75.9	413	74.7	

PrEP: pre-exposure prophylaxis.

^a Other defined as bisexual, straight or heterosexual, any other term or do not usually use a term.

Statistically significant p values (p < 0.05) are shown in bold.

with men (MSM) are disproportionately affected [2]. In pooled analyses of MSM with sexual risk behaviours, the overall STI incidence rate was 84.4 new infections per 100 person-years (PY), including 64.4 infections per 100 PY in a North American cohort, 99.8 infections per 100 PY in an Australian cohort and 97.8 new infections per 100 PY in a Dutch cohort [3].

The expansion of pre-exposure prophylaxis (PrEP) against HIV, may be accompanied by a change in behaviours that impact acquisition of other STI. Individuals who use PrEP may adjust their sexual behaviours based on their reduced risk for HIV acquisition and this risk compensation could include decreased condom use and/or an increase of partner numbers compared with those not on PrEP [4]. Other studies have not found such risk compensation but have described increased STI diagnoses as a consequence of improved case finding of asymptomatic infections when PrEP users are regularly screened [5]. In a meta-analysis of 88 studies examining gonorrhoea, chlamydia and syphilis among individuals using PrEP, the prevalence of these STI was 23.9% at PrEP initiation with an incidence of 72.2 new infections per 100 PY during PrEP use, i.e. within the range of new infections among all MSM [6]. In contrast, in a cross-sectional study of MSM in Germany, PrEP use was associated with increased odds of testing positive for at least one STI excluding HIV [7].

While several studies have examined the association between PrEP use and STI, many were secondary analyses of PrEP roll-out studies and consequently only examined STI among participants who initiated PrEP and did not include a comparison with non-users. In addition, most studies only tested for STI at one or two anatomical sites with a focus on gonorrhoea, chlamydia and syphilis, while ignoring other pathogens that are common among MSM such as the emerging sexually transmitted bacterium *Mycoplasma genitalium* (MG). Our objective was to comprehensively quantify the prevalence of STI at the screening visit for entry into a cohort of MSM at risk for HIV infection and evaluate potential associations between PrEP use and STI.

Methods

Study procedures

The *Longitudinal Incidence Study in Subtype B-prevalent Region Among MSM at Risk for HIV Infection to Determine Feasibility of HIV Vaccine Efficacy Trials* (BRAHMS) was a prospective study conducted at 10 sites in seven major German cities (Berlin, Bochum, Cologne, Essen, Frankfurt, Hamburg and Munich) that enrolled MSM at risk of HIV infection from 4 June 2018 to 3 July 2019. Individuals were eligible to enrol if they had a non-reactive HIV test, identified as male (either at birth, chosen or intersexual), were 18–55 years-old and met either of the following two risk criteria [1]: self-reported condomless anal intercourse with at least two unique male partners known to be living with HIV or with unknown HIV status in the past 24 weeks or [2]

documented history of syphilis, acute hepatitis C or rectal infection with MG, NG or CT in the past 24 weeks. Individuals were excluded from study participation if they previously participated in a candidate HIV vaccine study or were concurrently participating in any study of investigational agents for HIV prevention or treatment. Participants were allowed to enrol if they were taking approved agents for pre- or post-exposure prophylaxis, use of which was systematically documented.

At the screening visit to determine study eligibility, basic demographical data were collected and participants without HIV were counselled about PrEP. Blood was collected to test for HIV infection, active syphilis and hepatitis A, B and C. Urine and anal and pharyngeal swabs were collected to test for MG, NG, CT and TV. STI testing was performed according to standard diagnostic methods (see the Supplement for additional information on diagnostic testing). All study visits also included risk reduction counselling, provision of condoms and condom-compatible lubricants, and completion of sexual behaviour questionnaires. For these cross-sectional analyses, only data from the screening visit were included.


Clinical and behavioural data collection

At each visit, a comprehensive medical history was taken and an extensive medical record review was performed, which included documentation of any PrEP start and stop dates. Current PrEP use was defined by the presence of a PrEP start date and indication of ongoing use in medical records. Participants without PrEP use information recorded or a stop date before the study visit were classified as not currently on PrEP. Symptoms potentially associated with an STI that occurred within the last 30 days before study participation or were ongoing were documented overall and then by each individual symptom. For these analyses, only participants experiencing symptoms on the date of the visit were categorised as symptomatic.

At screening, participants completed a demographical and sociobehavioural questionnaire that assessed age, place of birth, education, gender identity, sexual orientation, number of male partners, condom use, recreational drug use and engagement in transactional sex. For both steady and casual partners, participants indicated the percentage of sex acts during which they were the receptive or insertive partner in the last 12 months. Sexual positioning was further classified, categorising participants as exclusively receptive, exclusively insertive or both. Condom use was assessed by asking the number of male steady or casual partners with whom the participant had condomless anal intercourse in the last 12 months. Participants who reported using a condom for anal intercourse with all male partners were classified as having consistent condom use while those reporting any condomless anal intercourse were categorised as less than consistent. Recreational drug use was assessed by asking about the last time a participant used poppers, sedatives or tranquilisers

FIGURE 1

Prevalence of sexually transmitted infections, in relation to anatomical site and use of HIV pre-exposure prophylaxis, Germany, June 2018–July 2019 (n = 1,043)



PrEP: pre-exposure prophylaxis; STI: sexually transmitted infection.

^a Several participants tested positive for STI at multiple anatomical sites.

or if they had ever taken any other recreational drug. Transactional sex was defined as either having paid or been paid to have sex with a man in the last 12 months.

Statistical analysis

Data were entered directly into the ArcGIS Survey123 platform (Esri, Redlands, United States (US)). Analyses were performed in Stata 16.0 (StataCorp, College Station, US).

Descriptive statistics used Kruskal-Wallis and Pearson chi-squared tests to compare demographical and behavioural characteristics between participants using and not using PrEP at the time of the screening visit. Log-binomial regression was used to estimate prevalence ratios (PR) and 95% confidence intervals (CI) for the association of current PrEP use and STI at the screening visit. We ran separate models examining the association of PrEP use with (i) a positive test for MG, NG, CT and/or TP, (ii) a positive NG or CT test, (iii) a

positive NG test and (iv) a positive CT test. There were no cases of TV and thus TV was not included in modelling. Model selection was performed using backwards selection with a p value < 0.05. Any variable qualifying for inclusion in one model was included in all models.

Ethical statement


The study was approved by institutional review boards of the Walter Reed Army Institute of Research, the University Duisburg–Essen and all collaborating institutions (registration number: 17–7598-BO; ClinicalTrials.gov ID: NCT03884816). All participants provided written informed consent for the study and publication of results before enrolment. The planning conduct and reporting of this study was in line with the Declaration of Helsinki, as revised in 2013.

Results

A total of 1,043 individuals were screened for the study, with 53.0% (n=553) using PrEP at the time of

FIGURE 2

Number of prevalent diagnoses of sexually transmitted infections by anatomical site, Germany, June 2018–July 2019 (n = 1,043)



'All STI' was defined as at least one of the following: *Mycoplasma genitalium* infection, gonorrhoea or chlamydia. Participants were classified as having a diagnosis at an anatomical site if they tested positive for any pathogens looked at in this study. For example a participant who had pharyngeal gonorrhoea and anorectal chlamydia would be classified as pharyngeal and anorectal in the 'All STI' Venn diagram. Participants with missing data for one of the anatomical sites were assumed negative at the site.

the screening visit. Among all participants, the median age was 33 years (interquartile range: 28–39), while participants currently using PrEP were slightly older than those who reported not to be on PrEP (34 vs 31 years; $p < 0.001$); (Table 1). The majority of participants identified as cisgender men (98.5%; $n = 1,027$) and as gay or homosexual (91.9%; $n = 959$).

Among the 907 participants reporting number of male partners at the screening visit, 692 (76.3%) reported more than 10 male partners in the preceding 12 months. The number of partners differed significantly between the two groups with 81.0% of participants on PrEP reporting more than five partners ($n = 448$) and 75.9% of participants not on PrEP reporting more than five partners ($n = 372$; $p < 0.001$). Compared with participants not reporting current PrEP use, a higher percentage of participants reporting current PrEP use reported less than consistent condom use with a steady partner (49.2% vs 44.5%; $p = 0.05$) or casual partner (76.7% vs 72.4%; $p < 0.001$) and using poppers within the last seven days (25.5% vs 22.0%; $p = 0.03$). Taken together, we found a slightly higher frequency of sexual partners as well as lower condom use among PrEP users compared with non-PrEP users.

High frequency of sexually transmitted infections among men who have sex with men

At the screening visits, we detected a high frequency of STI among all participants. Overall, 35.5% of participants had an STI ($n = 370$), including 27.3% ($n = 285$) who had a single STI, 7.6% ($n = 79$) with two STI, 1.1% ($n = 11$) with three STI and one individual with four STI. The most commonly observed pathogen was MG in 19.0% ($n = 198$) of participants, followed by CT (12.8%; $n = 133$), NG (10.1%; $n = 105$) and TP (3.5%; $n = 37$) (Figure 1A). Prevalence of HIV ($< 1\%$, $n = 4$), hepatitis B ($< 1\%$; $n = 2$) and hepatitis C ($< 1\%$; $n = 5$) was low and there were no participants with acute hepatitis A or with a TV infection. The most common simultaneously occurring infections were with NG and CT (2.2%; $n = 23$), followed by NG and MG (2.1%; $n = 22$) and CT and MG (1.7%; $n = 18$). There were an additional eight participants with MG and TP, five participants with CT and TP and two participants with NG and TP. Ten participants had MG, NG and CT, and one participant had MG, CT and TP.

Prevalence of sexually transmitted infections by anatomical site

The prevalence of STI was highest at the anorectal site (25.9%) followed by pharyngeal (10.3%) and urethral (9.0%) infections. The most common anorectal infection was MG, occurring in 13.4% of the participants, followed by NG (6.5%) and CT (10.2%; Figure 1). Examining the overlap of STI by anatomical site, 1.7% of participants had an STI at all three sites, while 6.1% tested positive for STI at both anorectal and pharyngeal sites (Figure 2). These data indicate that the same or different STI can occur simultaneously at different anatomical sites.

Low level of recorded symptoms among individuals with sexually transmitted infections

We assessed the symptoms of the 370 participants with at least one STI. Surprisingly, only 14.6% ($n = 54$) had symptoms. An additional 71 participants reported symptoms but did not test positive for any STI. The most frequently reported symptoms were sore throat ($n = 15$), pain or burning during urination ($n = 9$), and penile, urethral or neovaginal discharge ($n = 8$). Five participants reported painful swallowing, itching or other discomfort in the perianal area, pain or burning during defecation or difficulty urinating. Among the 54 participants reporting symptoms, 34 reported one symptom while 10 reported two, eight reported three, one participant reported four and one participant reported six symptoms.

Use of pre-exposure prophylaxis and sexually transmitted infections

We asked the question whether PrEP use was associated with increased levels of STI. Descriptively, only syphilis positivity differed significantly by PrEP use (4.7% vs 2.3%; $p = 0.03$) (Figure 1B) and there were no significant differences in STI by anatomical site and

TABLE 2

Adjusted prevalence ratios for HIV pre-exposure prophylaxis usage and other factors potentially associated with *Mycoplasma genitalium* infection, gonorrhoea, chlamydia or syphilis, Germany, June 2018–July 2019 (n = 1,043)

	Any STI ^a		Gonorrhoea or chlamydia		Gonorrhoea		Chlamydia	
	aPR	95% CI	aPR	95% CI	aPR	95% CI	aPR	95% CI
PrEP								
Not using PrEP	Reference							
Using PrEP	1.10	0.91–1.32	1.00	0.76–1.32	0.92	0.61–1.37	1.06	0.74–1.51
Education								
Less than a university degree	Reference							
University degree or higher	0.88	0.73–1.05	0.82	0.62–1.07	0.83	0.56–1.24	0.78	0.55–1.13
Number of partners (last 12 months)								
≤5	Reference							
>5	2.01	1.24–3.25	1.74	0.93–3.27	2.11	0.79–5.60	1.60	0.73–3.52
Sexual positioning								
Not applicable or missing information	0.95	0.62–1.44	0.54	0.24–1.19	0.90	0.03–2.71	0.25	0.05–1.17
Exclusively receptive	Reference							
Exclusively insertive	0.64	0.36–0.92	0.20	0.05–0.83	0.43	0.09–2.09	0.19	0.02–1.54
Both insertive and receptive	0.80	0.62–1.05	0.61	0.37–1.01	0.68	0.29–1.58	0.77	0.36–1.64

aPR: adjusted prevalence ratio; CI: confidence interval; PrEP: pre-exposure prophylaxis.

^a Any sexually transmitted infection defined as at least one of the following: *Mycoplasma genitalium* infection, gonorrhoea, chlamydia or syphilis.

PrEP use (Figure 1D). None of the four participants with HIV reported PrEP use, while two participants with hepatitis B and two with hepatitis C were on PrEP. In the unadjusted model, PrEP use was not significantly associated with overall prevalence of any STI (MG, NG, CT or TP; PR: 1.17; 95% CI: 0.99–1.39; Supplementary Table S1 provides unadjusted PR) and was not statistically significant in the adjusted model (adjusted PR: 1.10; 95% CI: 0.91–1.32) (Table 2). There was no significant association between PrEP use and NG/CT in the unadjusted and adjusted models (Table 2, Supplementary Table S2 provides additional unadjusted PR for the association between select factors and NG/CT) nor in the model examining only NG (Table 2, Supplementary Table S3 provides unadjusted PR for NG) or only CT (Table 2). Taken together, we did not observe significant differences in STI in a point prevalence analysis between PrEP users and non-PrEP users.

Discussion

In this cohort of predominantly MSM at risk for HIV in Germany, STI prevalence was high at baseline screening, especially with the emerging sexually transmitted bacterial infection MG. Compared with a similar cohort of MSM in France enrolled from 2015 to 2016, MG prevalence in our cohort was nearly twice as high [8]. A meta-analysis of MG among MSM globally reported a prevalence of 3.2% (95% CI: 2.1–5.1%) [9]. However, other studies have found similar prevalence as ours with 15% prevalence among asymptomatic MSM in Australia [10] and 17% among care-seeking men in the US [11]. Our findings were in line with another cross-sectional analysis from 2018 of MSM on PrEP in Germany with a 20% prevalence of MG, although they had a slightly

lower prevalence among MSM not on PrEP [7]. MG is increasingly recognised as a cause of non-gonococcal, non-chlamydial urethritis in men [12,13] as well as asymptomatic rectal infection and symptomatic proctitis among MSM [14,15]. There is in vitro evidence that MG may facilitate HIV infection through mucosal disruption [16,17], an inflammatory response that recruits HIV-susceptible cells to the mucosal surface [18], and direct enhancement of HIV replication [19,20]. Routine screening for MG is not currently recommended in Germany. Given the high prevalence of asymptomatic disease, potential for morbidity and enhanced risk of HIV transmission, routine screening for MG could be considered for German MSM, although management of asymptomatic MG infection is unclear and requires further investigation. In this context, the high levels of antimicrobial resistance of MG in MSM against macrolides and increasing resistance against quinolones are of special importance [21,22].

We also found a high prevalence of gonorrhoea and chlamydia. A meta-analysis of 12 studies found a similar CT prevalence of 10.8%, although the prevalence varied slightly more by anatomical site as in our cohort (4% urogenital prevalence and 8.5% rectal) [6]. Another German study found a similar prevalence of NG (8.9%) but a lower prevalence of CT (9.9%), with a similar distribution across anatomical sites as seen in our study [7]. In a care-seeking sample of MSM in Portugal, prevalence of NG was 10.7% and prevalence of CT was at 7.6% less than half of the prevalence in the BRAHMS cohort [23]. The discrepancy in CT prevalence may be due in part to the different inclusion criteria for the respective studies as the Portuguese study included

any care-seeking individual who had results for CT/NG tests at all three anatomical sites. Lower prevalence of STI in other studies may also be due to testing only one or two anatomical sites. Systematic testing for STI at all three anatomical sites among participants in our study provides a comprehensive understanding of the burden of infection and the cases that may be missed when only one or two anatomical sites are evaluated. Testing only at the anorectal site would have missed 23% of infections in this study.

We found a comparably low prevalence of syphilis, hepatitis B and C and no cases of hepatitis A or of TV infection. In a meta-analysis of individuals using PrEP, pooled prevalence of syphilis (5.0%) was similar to our findings but the prevalence of hepatitis A (5.4%), hepatitis B (1.3%), hepatitis C (2.0%) and TV (5.9%) was higher [6]. Co-infection with multiple STI was less common in our study than in similar cohorts elsewhere: In a study of MSM in Australia, 13% of participants with CT also had MG and 14% were coinfecting with MG and NG [24]. Among care-seeking MSM in London, 7% had CT/NG coinfections [25]. The difference in prevalence in these various groups may be due to the criteria for inclusion in the studies as some involved only care-seeking or symptomatic individuals.

We also found that PrEP use had no association with STI in cross-sectional analyses. Other cohort studies have found an increase in STI after initiation of PrEP [3,26,27]. The mechanism for these findings could relate to increased screening among individuals on PrEP or HIV risk compensation behaviours beyond condom use such as increasing partner numbers. In another study of German MSM, PrEP use was associated with twice the odds of any STI (95% CI: 1.5–2.7) [7]. While both studies examined care-seeking MSM attending MSM-friendly practices, BRAHMS recruited individuals reporting sexual behaviours with increased risk for acquiring STI or with recent known history of STI, so we expected the differences in sexual risk behaviour between PrEP and non-PrEP users in our study to be less pronounced. A randomised controlled trial in 13 sexual health clinics in England assessed the effect of risk compensation in users of PrEP and found no difference in STI occurrence [28]. We also found no significant association between PrEP use and NG/CT. This finding is in agreement with a clinic-based study among MSM in the US, where CT prevalence remained constant at 9.6% before and after PrEP initiation and NG prevalence remained stable (11.7% vs 10.3%) before and after PrEP initiation [5]. We found small differences in engaging in sexual risk behaviours comparing PrEP users to non-users; this may be due to the inclusion criteria and the risk profile that was required to fulfil eligibility for this study. In addition, participants in our study were engaged in care at centres specialising in providing care to sexual and gender minorities at risk for HIV; good counselling practices may have impacted the lack of risk compensation observed in our study as compared with others. Our study makes it clear that

regular screening for STI is an important component of caring for behaviourally vulnerable to STI German men regardless of PrEP use. Concern about risk compensation should not be a barrier to PrEP use in men with behavioural risk factors for HIV acquisition.

The high prevalence of STI in a mostly asymptomatic cohort of MSM suggests the importance of regular STI screening. Testing only symptomatic individuals would have missed 85% of infections in this population. Other studies have similarly found a predominance of asymptomatic infections among MSM [7,29,30]. Effective screening practices should also include anatomically appropriate screening and testing at multiple anatomical sites. While the prevalence was highest among anorectal STI, we also found pathogens present in both pharyngeal and urogenital samples, highlighting the need for screening at all sites. In a meta-analysis of 12 STI and PrEP use studies, among participants with positive NG tests, 13.8% had both positive anorectal and pharyngeal tests while 2.5% had positive pharyngeal, anal and urogenital tests [23]. The decision to treat asymptomatic infections with MG, NG and CT needs to weigh advantages in terms of STI sequelae with the potential damages to the microbiome caused by frequent use of antibiotics.

Strengths of this study include the extensive medical record review of PrEP data, medical history and testing for a wide array of STI at multiple anatomical sites. However, this study is not without limitations. Firstly, the cross-sectional nature of our analyses does not allow for any comment on causality in the association between PrEP use and STI. However, these analyses provide a snapshot of the STI prevalence among MSM at risk for HIV who were engaged in routine care before entry into a cohort study that included enhanced STI testing. Secondly, results for lymphogranuloma venereum were not available at the time of this analysis which may explain some of the reported rectal symptoms. Thirdly, we only present symptom information at the time of STI testing which may underestimate actual symptomatic infections if symptoms in the previous weeks were not serious enough to seek medical advice. Fourthly, the risk profile required to enrol in BRAHMS, allowing only for men at high risk of HIV infection, and the active counselling as part of study procedures may make these findings not generalisable to other populations, but can serve as a good basis for diagnostic and treatment decisions for MSM eligible for PrEP. Finally, the clinics from which participants were enrolled cater to gender and sexual minorities and have expertise in HIV prevention and treatment for these populations.

Conclusion

We found a high prevalence of asymptomatic rectal STI in a cohort of behaviourally vulnerable MSM as well as a high prevalence of STI in both urogenital and oropharyngeal sites, highlighting a need for regular and comprehensive screening at several sites.

Acknowledgements

We are grateful to all study participants. We thank the BRAHMS study team for executing this important work. This study was supported by the U.S. Military HIV Research Program (MHRP) under cooperative agreements between the U.S. Army and the Henry M. Jackson Foundation for the Advancement of Military Medicine (W81XWH-11-2-0174; W81XWH-18-2-0040) with support from the US Army Medical Research and Development Command (W81XWH-18-C-0077), Pharmaceutical Systems PMO, HIV Vaccine Program, the Bundesministerium für Gesundheit (BMG) and the Division of AIDS (DAIDS), National Institutes of Health (NIH). The views expressed are those of the authors and should not be construed to represent the positions of the U.S. Army or the Department of Defense. We thank Hologic for providing laboratory diagnostic support to the study.

Prior presentation: This work was presented, in part, at IAS 2019 in Mexico City, Mexico, 21-24 July 2019.

Conflict of interest

None declared.

Authors' contributions

HS, KJ and TAC conceived of the presented research idea. AE designed the statistical model, analysed the data and authored the first draft of the research manuscript. KJ, TAC and UM helped to refine the statistical approach. HJ, CC, SScho, SSchn, NB, CDS, MB, SE, JH, AS and CL, carried out the data collection. JJV and CT oversaw laboratory activities. AK and AB provided project management support and reviewed the collected data for quality and reliability. HS, KJ, TAC, MLR and NLM contributed to the interpretation of the results. HS, MLR and NLM provided overall direction and planning for the BRAHMS study. All authors provided critical feedback and helped shape the research, analysis and manuscript, including review and approval of the manuscript in its final form

References

1. World Health Organization (WHO). Report on global sexually transmitted infection surveillance. Geneva: WHO; 2018. ISBN: 978-92-4-156569-1. Available from: <https://www.who.int/reproductivehealth/publications/stis-surveillance-2018>
2. European Centre for Disease prevention and Control (ECDC). HIV and STI prevention among men who have sex with men. Stockholm: ECDC; 2015. Available from: <https://www.ecdc.europa.eu/sites/portal/files/media/en/publications/Publications/hiv-sti-prevention-among-men-who-have-sex-with-men-guidance.pdf>
3. Werner RN, Gaskins M, Nast A, Dressler C. Incidence of sexually transmitted infections in men who have sex with men and who are at substantial risk of HIV infection - A meta-analysis of data from trials and observational studies of HIV pre-exposure prophylaxis. *PLoS One*. 2018;13(12):e0208107. <https://doi.org/10.1371/journal.pone.0208107> PMID: 30507962
4. Brooks RA, Landovitz RJ, Kaplan RL, Lieber E, Lee S-J, Barkley TW. Sexual risk behaviors and acceptability of HIV pre-exposure prophylaxis among HIV-negative gay and bisexual men in serodiscordant relationships: a mixed methods study. *AIDS Patient Care STDS*. 2012;26(2):87-94. <https://doi.org/10.1089/apc.2011.0283> PMID: 22149764
5. Beymer MR, DeVost MA, Weiss RE, Dierst-Davies R, Shover CL, Landovitz RJ, et al. Does HIV pre-exposure prophylaxis use lead to a higher incidence of sexually transmitted infections? A case-crossover study of men who have sex with men in Los Angeles, California. *Sex Transm Infect*. 2018;94(6):457-62. <https://doi.org/10.1136/sextrans-2017-053377> PMID: 29487172
6. Ong JJ, Baggaley RC, Wi TE, Tucker JD, Fu H, Smith MK, et al. Global epidemiologic characteristics of sexually transmitted infections among individuals using preexposure prophylaxis for the prevention of HIV infection: a systematic review and meta-analysis. *JAMA Netw Open*. 2019;2(12):e1917134. <https://doi.org/10.1001/jamanetworkopen.2019.17134> PMID: 31825501
7. Jansen K, Steffen G, Potthoff A, Schuppe AK, Beer D, Jessen H, et al. STI in times of PrEP: high prevalence of chlamydia, gonorrhoea, and mycoplasma at different anatomic sites in men who have sex with men in Germany. *BMC Infect Dis*. 2020;20(1):110. <https://doi.org/10.1186/s12879-020-4831-4> PMID: 32033533
8. Berçot B, Charreau I, Rousseau C, Delaugerre C, Chidiac C, Pialoux G, et al. High prevalence and high rate of antibiotic resistance of *Mycoplasma genitalium* infections in men who have sex with men. a substudy of the ANRS IPERGAY pre-exposure prophylaxis trial. *Clin Infect Dis*. 2021;73(7):e2127-33. <https://doi.org/10.1093/cid/ciaa1832> PMID: 33305785
9. Baumann L, Cina M, Egli-Gany D, Goutaki M, Halbeisen FS, Lohrer GR, et al. Prevalence of *Mycoplasma genitalium* in different population groups: systematic review and meta-analysis. *Sex Transm Infect*. 2018;94(4):255-62. <https://doi.org/10.1136/sextrans-2017-053384> PMID: 29440466
10. Read TRH, Murray GL, Danielewski JA, Fairley CK, Doyle M, Worthington K, et al. Symptoms, sites, and significance of *Mycoplasma genitalium* in men who have sex with men. *Emerg Infect Dis*. 2019;25(4):719-27. <https://doi.org/10.3201/eid2504.181258> PMID: 30882306
11. Getman D, Jiang A, O'Donnell M, Cohen S. *Mycoplasma genitalium* prevalence, coinfection, and macrolide antibiotic resistance frequency in a multicenter clinical study cohort in the United States. *J Clin Microbiol*. 2016;54(9):2278-83. <https://doi.org/10.1128/JCM.01053-16> PMID: 27307460
12. Pond MJ, Nori AV, Witney AA, Lopeman RC, Butcher PD, Sadiq ST. High prevalence of antibiotic-resistant *Mycoplasma genitalium* in nongonococcal urethritis: the need for routine testing and the inadequacy of current treatment options. *Clin Infect Dis*. 2014;58(5):631-7. <https://doi.org/10.1093/cid/cit752> PMID: 24280088
13. Moi H, Reinton N, Moghaddam A. *Mycoplasma genitalium* is associated with symptomatic and asymptomatic nongonococcal urethritis in men. *Sex Transm Infect*. 2009;85(1):15-8. <https://doi.org/10.1136/sti.2008.032730> PMID: 18842690
14. Bissessor M, Tabrizi SN, Bradshaw CS, Fairley CK, Hocking JS, Garland SM, et al. The contribution of *Mycoplasma genitalium* to the aetiology of sexually acquired infectious proctitis in men who have sex with men. *Clin Microbiol Infect*. 2016;22(3):260-5. <https://doi.org/10.1016/j.cmi.2015.11.016> PMID: 26686807
15. Crowell TA, Lawlor J, Lombardi K, Nowak RG, Hardick J, Odeyemi S, et al. Anorectal and urogenital *Mycoplasma genitalium* in Nigerian men who have sex with men and transgender women: prevalence, incidence, and association with HIV. *Sex Transm Dis*. 2020;47(3):202-6. <https://doi.org/10.1097/OLQ.0000000000001105> PMID: 31880740
16. Tully JG, Taylor-Robinson D, Rose DL, Furr PM, Graham CE, Barile MF. Urogenital challenge of primate species with *Mycoplasma genitalium* and characteristics of infection induced in chimpanzees. *J Infect Dis*. 1986;153(6):1046-54. <https://doi.org/10.1093/infdis/153.6.1046> PMID: 3701116
17. Zhang S, Wear DJ, Lo S. Mycoplasma infections alter gene expression in cultured human prostatic and cervical epithelial cells. *FEMS Immunol Med Microbiol*. 2000;27(1):43-50. <https://doi.org/10.1111/j.1574-695X.2000.tb01410.x> PMID: 10617789
18. McGowin CL, Annan RS, Quayle AJ, Greene SJ, Ma L, Mancuso MM, et al. Persistent *Mycoplasma genitalium* infection of human endocervical epithelial cells elicits chronic inflammatory cytokine secretion. *Infect Immun*. 2012;80(11):3842-9. <https://doi.org/10.1128/IAI.00819-12> PMID: 22907815
19. Sasaki Y, Honda M, Makino M, Sasaki T. *Mycoplasmas* stimulate replication of human immunodeficiency virus type 1 through selective activation of CD4+ T lymphocytes. *AIDS Res Hum Retroviruses*. 1993;9(8):775-80. <https://doi.org/10.1089/aid.1993.9.775> PMID: 8105836
20. Phillips DM, Pearce-Pratt R, Tan X, Zacharopoulos VR. Association of mycoplasma with HIV-1 and HTLV-I in human T lymphocytes. *AIDS Res Hum Retroviruses*. 1992;8(11):1863-8. <https://doi.org/10.1089/aid.1992.8.1863> PMID: 1489576
21. Spornraft-Ragaller P, Dumke R. Prevalence and antibiotic resistance of rectal mollicutes in HIV-infected men who have sex with men at the University Hospital of Dresden, Germany. *Infection*. 2020;48(2):259-65. <https://doi.org/10.1007/s15010-019-01386-3> PMID: 31993971
22. Dumke R, Rust M, Glaunsinger T. MgpB types among *Mycoplasma genitalium* strains from men who have sex with men in Berlin, Germany, 2016-2018. *Pathogens*. 2019;9(1):2016-8. <https://doi.org/10.3390/pathogens9010012> PMID: 31861901

23. Ribeiro S, de Sousa D, Medina D, Castro R, Lopes Â, Rocha M. Prevalence of gonorrhoea and chlamydia in a community clinic for men who have sex with men in Lisbon, Portugal. *Int J STD AIDS*. 2019;30(10):951-9. <https://doi.org/10.1177/0956462419855484> PMID: 31284840
24. Latimer RL, Vodstrcil L, De Petra V, Fairley CK, Read TRH, Williamson D, et al. Extragenital *Mycoplasma genitalium* infections among men who have sex with men. *Sex Transm Infect*. 2020;96(1):10-8. <https://doi.org/10.1136/sextrans-2019-054058> PMID: 31217322
25. Broad CE, Furegato M, Harrison MA, Pond MJ, Tan N, Okala S, et al. High prevalence of coinfection of azithromycin-resistant *Mycoplasma genitalium* with other STIs: a prospective observational study of London-based symptomatic and STI-contact clinic attendees. *Sex Transm Infect*. 2021;97(1):63-8. <https://doi.org/10.1136/sextrans-2019-054356> PMID: 32393529
26. Noret M, Balavoine S, Pintado C, Siguier M, Brun A, Bauer R, et al. Daily or on-demand oral tenofovir disoproxil fumarate/emtricitabine for HIV pre-exposure prophylaxis: experience from a hospital-based clinic in France. *AIDS*. 2018;32(15):2161-9. <https://doi.org/10.1097/QAD.0000000000001939> PMID: 30212403
27. Montaña MA, Dombrowski JC, Dasgupta S, Golden MR, Duerr A, Manhart LE, et al. Changes in sexual behavior and STI diagnoses among MSM initiating PrEP in a clinic setting. *AIDS Behav*. 2019;23(2):548-55. <https://doi.org/10.1007/s10461-018-2252-9> PMID: 30117076
28. McCormack S, Dunn DT, Desai M, Dolling DI, Gafos M, Gilson R, et al. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. *Lancet*. 2016;387(10013):53-60. [https://doi.org/10.1016/S0140-6736\(15\)00056-2](https://doi.org/10.1016/S0140-6736(15)00056-2) PMID: 26364263
29. Turner AN, Reese PC, Ervin M, Davis JA, Fields KS, Bazan JA. HIV, rectal chlamydia, and rectal gonorrhoea in men who have sex with men attending a sexually transmitted disease clinic in a midwestern US city. *Sex Transm Dis*. 2013;40(6):433-8. <https://doi.org/10.1097/OLQ.0b013e31828fd163> PMID: 23677015
30. Keshinro B, Crowell TA, Nowak RG, Adebajo S, Peel S, Gaydos CA, et al. High prevalence of HIV, chlamydia and gonorrhoea among men who have sex with men and transgender women attending trusted community centres in Abuja and Lagos, Nigeria. *J Int AIDS Soc*. 2016;19(1):21270. <https://doi.org/10.7448/IAS.19.1.21270> PMID: 27931519

License, supplementary material and copyright

This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate credit to the source, provide a link to the licence and indicate if changes were made.

Any supplementary material referenced in the article can be found in the online version.

This article is copyright of the authors or their affiliated institutions, 2022.